Europe Diagnostic Enzymes Market Size, Share, and COVID-19 Impact Analysis, By Enzyme Type (Oxidoreductase, Transferase, Hydrolases, and Ligase), By Application (Cardiovascular Diagnostics, Diabetes Management, Liver Function Testing, Cancer Diagnosis), By End User (Hospitals and Clinics, Diagnostic Laboratories, and Point-of-Care Setting), and Europe Diagnostic Enzymes Market Insights, Industry Trends, Forecast to 2035

Europe Diagnostic Enzymes Market Insights Forecasts to 2035

• The Europe Diagnostic Enzymes Market Size Was Estimated at USD 1428.3 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 8.1% from 2025 to 2035
• The Europe Diagnostic Enzymes Market Size is Expected to Reach USD 3365.3 Million by 2035

According to a research report published by Spherical Insights & Consulting, The Europe Diagnostic Enzymes Market Size is Anticipated to Reach USD 3365.3 Million by 2035, Growing at a CAGR of 8.1% from 2025 to 2035. The market is driven by the growing number of elderly people, rising healthcare costs, government programs, growing awareness of preventative healthcare, and the incidence of chronic diseases.

Market Overview

The market of diagnostic enzymes is specialized biocatalysts that are mostly employed in biochemistry labs, biosensors, and clinical diagnostics to catalyze processes that reveal important biochemical indicators. The way laboratories identify disease biomarkers, confirm treatment targets, and standardize diagnostic procedures has been revolutionized by developments in enzyme characterisation, assay development, and high-throughput screening. Diagnostic enzymes are essential enzymes that are used either directly or as parts of assay systems to identify the presence or absence of certain substances.

To increase the availability of its cutting-edge nucleic acid products to clients throughout Europe, the Middle East, and Africa, TriLink Biotechnologies, a Maravai LifeSciences company and worldwide supplier of life science reagents and services, partnered with Avantor, Inc., a top supplier of mission-critical goods and services to clients in the life sciences and advanced technology industries, in February 2025.

Enzyme-based assays are anticipated to be required as artificial intelligence (AI) and machine learning are included in diagnostic systems. Since diagnostic enzymes are crucial parts of POC treatments for a variety of ailments, the trend toward quick and reliable diagnostics outside of conventional clinical settings is a major motivator.

Report Coverage

This research report categorizes the market for the Europe diagnostic enzymes market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Europe Diagnostic Enzymes Market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Europe diagnostic enzymes market.

Driving Factors

The Europe Diagnostic Enzymes Market Size in Europe is driven by the increasing rate of chronic diseases such as cancer, diabetes, heart disease, and liver diseases. The factors leading to this increase have been the development of diagnostic devices that not only allow but also encourage the detection of diseases at an early stage to get better treatment results. Increase in investments and progress in medical infrastructure in the developing areas. The presence of government health insurance, along with reimbursement programs, confirms the accessibility of enzyme-based diagnostic tests to the wider public, thus promoting the market growth even more.

Restraining Factors

The diagnostic enzymes market in Europe is restrained due to the high price tag attached to enzyme-based diagnostic tests, and the approval process for diagnostic enzymes is very stringent and has very high standards for quality assurance, safety, and efficacy. The lack of adequately trained healthcare staff.

Market Segmentation

The Europe diagnostic enzymes market share is categorised into enzyme type, application, and end user.

• The oxidoreductase segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Europe Diagnostic Enzymes Market Size is segmented by enzyme type into oxidoreductase, transferase, hydrolases, and ligase. Among these, the oxidoreductase segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. In 2024, oxidoreductase enzymes produced around 41% of the total sales due to their function in biosensors and clinical analyzers for glucose and cholesterol testing, which are considered the most common applications of these enzymes. Additionally, these enzymes are involved in redox reactions and are therefore suitable for high-throughput diagnostic formats due to their speed and sensitivity.

• The diabetes management segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

Based on application, the Europe Diagnostic Enzymes Market Size is segmented into cardiovascular diagnostics, diabetes management, liver function testing, cancer diagnosis. Among these, the diabetes management segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The segmental growth is driven by the high and increasing prevalence of diabetes in Europe, continuous and regular monitoring needs, and enzymes' significant role enzymes play in diagnostic test kits are the main reasons for the widespread use and reliance on HbA1c and enzyme-based glucose testing, along with universal healthcare that supports routine screening and monitoring in the country.

• The hospitals and clinics segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Europe Diagnostic Enzymes Market Size is segmented by end user into hospitals and clinics, diagnostic laboratories, and point-of-care settings. Among these, the hospitals and clinics segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The growth of the segment is driven by the hospitals are the central places for inpatient as well as outpatient treatment, and they carry out large numbers of diagnostic tests, which need enzyme-based methods. European hospitals see the advantages of clinical workflow integration that includes the use of automated analyzers and the direct connection to EMRs, which help in the smooth process of using diagnostic enzymes.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Europe diagnostic enzymes market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies                                                                                                                         

• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• BBI Solutions
• Biocatalysts Ltd
• Qiagen N.V.
• Novonesis
• Kaneka EurogentecS.A.
• Solis BioDyne
• Roche
• Thermo Fisher
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

In December 2025, Dyadic Applied BioSolutions announced a commercial agreement with Opes Diagnostics Limited to enhance the market launch of its recombinant proteins and enzymes, including human and bovine transferrin and FGF products, for serum-free cell culture media applications in various sectors such as life science and food.

Market Segment

This study forecasts revenue at the Europe, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Europe diagnostic enzymes market based on the below-mentioned segments:

Europe Diagnostic Enzymes Market, By Enzyme Type

• Oxidoreductase
• Transferase
• Hydrolases
• Ligase

Europe Diagnostic Enzymes Market, By Application

• Cardiovascular Diagnostics
• Diabetes Management
• Liver Function Testing
• Cancer Diagnosis

Europe Diagnostic Enzymes Market, By End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Point-of-Care Setting